Joanna K. Boyd, Jonathan Barratt  Kidney International 

Slides:



Advertisements
Similar presentations
Protein secretion: Getting folded proteins across membranes
Advertisements

The Differentiation of Vertebrate Immune Cells
The Leptin Connection: Regulatory T Cells and Autoimmunity
The Th17 immune response in renal inflammation
Gluten and IgA nephropathy: you are what you eat?
Adjuvants: Immunostimulatory
Immunomodulation in the critically ill
From mesothelioma to cardiovascular protection via the phosphoinositide-3 kinase pathway: A new vista in cardiothoracic surgery  Igor E. Konstantinov,
Jean-Claude Davin, Ineke J. Ten Berge, Jan J. Weening 
Beyond genetics: epigenetic code in chronic kidney disease
Rapamycin in transplantation: A review of the evidence
Innate immunity as a driving force in renal disease
Hyun Gyu Lee, Hoon Young Choi, Jong-Sup Bae  Kidney International 
Dieter Demon, Lieselotte Vande Walle, Mohamed Lamkanfi 
Status of chronic kidney disease prevention programs: International Federation of Kidney Foundation Members 2005/2007  Joanna M. Smith, Susan A. Mott,
Figure 3 Effect of sialylated glycoforms on IgG activity
Volume 80, Issue 10, Pages (November 2011)
Intestinal Permeability Defects: Is It Time to Treat?
G protein β3 subunit C825T polymorphism in primary IgA nephropathy
The Differentiation of Vertebrate Immune Cells
Neil J. Weiner, Jeffrey W. Goodman, Paul L. Kimmel 
Epigenetics Drives RAGs to Recombination Riches
Volume 58, Issue 1, Pages (July 2000)
Volume 85, Issue 3, Pages (March 2014)
Better nephrology for mice—and man
Volume 80, Issue 12, Pages (December 2011)
YouFei Guan, M.D., Ph.D., Matthew D. Breyer  Kidney International 
Gregory B. Vanden Heuvel  Kidney International 
Modulation of inflammation by chondroitin sulfate
Volume 146, Issue 4, Pages e1 (April 2014)
The genetic susceptibility to IgA nephropathy: A novel functional candidate gene for incomplete O-glycosylation of IgA1  I. Narita, Y. Kaneko, D. Kondo,
Cyclooxygenase-2 in the kidney: good, BAD, or both?
An update on the pathogenesis and treatment of IgA nephropathy
Frank Eitner, Jürgen Floege  Kidney International 
Volume 80, Issue 1, Pages (July 2011)
Toll Meets Bacterial CpG-DNA
Volume 85, Issue 3, Pages (March 2014)
David M. Charytan, John P. Forman  Kidney International 
Volume 135, Issue 1, Pages (July 2008)
IgA nephropathy at two score and one
Katherine A. Barraclough, E. Geoffrey Playford  Kidney International 
Matrix metalloproteinases and matrix receptors in progression and reversal of kidney disease: therapeutic perspectives  Pierre Ronco, Christos Chatziantoniou 
Volume 60, Issue 3, Pages (September 2001)
Volume 69, Issue 8, Pages (April 2006)
EMT and proteinuria as progression factors
Brad H. Rovin, Ling Lu, Xiaolan Zhang  Kidney International 
Inflammation and hypoxia in the kidney: friends or foes?
Role of macromolecular IgA in IgA nephropathy
Paola Romagnani, Hans-Joachim Anders  Kidney International 
NODding off in acute kidney injury with progranulin?
Stephen O'Neill, Jeremy Hughes  Kidney International 
Volume 57, Issue 4, Pages (April 2000)
Atherosclerotic nephropathy
Volume 69, Issue 5, Pages (March 2006)
Molecular Therapy  Volume 21, Pages S247-S248 (May 2013)
Volume 73, Issue 8, Pages (April 2008)
Transcription factor-κB (NF-κB) and renal disease
Is complement a target for therapy in renal disease?
Learning Tolerance while Fighting Ignorance
Gene targeting: Applications in transplantation research
Antimicrobial Defense of the Intestine
Membranous nephropathy: recent travels and new roads ahead
T cells and T-cell receptors in acute renal failure
Another niche for Notch
Novel aspects of complement in kidney injury
Volume 80, Issue 9, Pages (November 2011)
Corin: a serine protease
Volume 75, Issue 8, Pages (April 2009)
IgA nephropathy: Immune mechanisms beyond IgA mesangial deposition
Volume 7, Issue 1, Pages 1-11 (July 1997)
Presentation transcript:

Inherited IgA glycosylation pattern in IgA nephropathy and HSP nephritis: where do we go next?  Joanna K. Boyd, Jonathan Barratt  Kidney International  Volume 80, Issue 1, Pages 8-10 (July 2011) DOI: 10.1038/ki.2011.83 Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 1 Potential pathways responsible for determining the composition of serum IgA1 O-glycoforms in IgA nephropathy and Henoch–Schönlein purpura nephritis. The initial event in O-glycosylation of the IgA1 hinge region is the addition of N-acetylgalactosamine (GalNAc) to threonine or serine residues, which is under the control of UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2 (pp-GalNAc-T2). GalNAc may then be either sialylated in an α2,6-linkage or galactosylated via a β1,3-linkage. It has been proposed that sialylation of GalNAc prevents further extension of the core 1 structure with galactose, and that therefore the balance between the activity of α2,6-sialyltransferase and the activity of core 1 β1,3-galactosyltransferase (C1β3Gal-T) determines the synthesis of poorly galactosylated IgA1 O-glycoforms. The function of C1β3Gal-T is dependent on the presence of a molecular chaperone, Cosmc. α2,3-Sialyltransferase catalyzes the terminal sialylation of galactosylated GalNAc. Polymorphisms within the genes encoding these O-glycosyltransferases could result in production of poorly galactosylated IgA1; however, there is little convincing evidence to suggest this is the case in IgAN and HSPN. External factors, which are also likely to be subject to genetic variation, may influence glycosyltransferase activity and drive IgA1-committed plasma cells to synthesize poorly galactosylated IgA1. These include B-cell imprinting at the time of mucosal antigen encounter, cytokine expression within the local microenvironment, and Toll-like receptor activation by bacterial lipopolysaccharide (LPS) and bacterial DNA sequences with unmethylated cytosine–guanine dinucleotide (CpG) motifs. Alternatively, it is possible that plasma-cell glycosyltransferase activity is completely normal in IgAN and HSPN, but because of translocation of mucosally imprinted B cells to systemic sites due to faulty homing signals, these plasma cells release normal ‘mucosal-type’ polymeric poorly galactosylated IgA1 directly into the circulation rather than into the submucosa for transport across the mucosal epithelium and into mucosal secretions. IL-4, interleukin-4; LBP, LPS binding protein. Kidney International 2011 80, 8-10DOI: (10.1038/ki.2011.83) Copyright © 2011 International Society of Nephrology Terms and Conditions